HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer

Ovarian cancer is the most lethal gynecological malignancy. Recurrence and chemoresistance are tough challenges leading to poor prognosis. HJURP is a molecular chaperone of CENP-A, which is associated with aggressive progression in multiple tumors. However, the function of HJURP in ovarian cancer ha...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of biological sciences 2022, Vol.18 (3), p.1188-1210
Hauptverfasser:	Dou, Zhiyuan, Qiu, Chunping, Zhang, Xun, Yao, Shu, Zhao, Chen, Wang, Zixiang, Chu, Ran, Chen, Jingying, Chen, Zhongshao, Li, Rongrong, Wang, Kun, Liu, Penglin, Liu, Chang, Song, Kun, Kong, Beihua
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Apoptosis Biomarkers Breast cancer Cancer Cancer therapies Cell culture Cell cycle Cell Cycle Proteins - metabolism Cell Line, Tumor Cell proliferation Chemoresistance Cisplatin Cisplatin - pharmacology Cisplatin - therapeutic use Combined treatment Cyclin-dependent kinases Cystadenocarcinoma, Serous DNA damage DNA repair Fallopian tubes Female Gene expression Humans Kinases Laboratories Lung cancer Malignancy Medical prognosis Metastases Myc protein Next-generation sequencing Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Prognosis Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - metabolism Proteins Reagents Research Paper Sensitivity enhancement Synergistic effect Therapeutic targets Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!